Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: Spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 339-347

  Safdar, A ^a   Rodriguez, G H ^a   Mihu, C N ^a   Mora Ramos, L ^a   Mulanovich, V ^a   Chemaly, R F ^a   Champlin, R E ^b   Khouri, I ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Antimicrobial prophylaxis; Guidelines; Infections; Non myeloablative stem cell transplantation; Stem cell transplantation

Indexed keywords

ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; COTRIMOXAZOLE; FLUCONAZOLE; FOSCARNET; LEVOFLOXACIN; METHOTREXATE; STEROID; SULFONAMIDE; TACROLIMUS; UNCLASSIFIED DRUG; VALGANCYCLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DONOR SELECTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HUMAN; INFECTION RISK; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; PNEUMONIA; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RNA VIRUS INFECTION; SEPSIS; SINUSITIS; SPECIES INVASION; SYMPTOMATOLOGY; VIREMIA; VIRUS INFECTION;

ADULT; AGED; BACTERIAL INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYCOSES; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 76749144119     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.149     Document Type: Article

References (44)

1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
2. Giralt S, Khouri I, Champlin R. Non myeloablative 'mini transplants'. Cancer Treat Res 1999; 101: 97-108.
3. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
4. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023.
5. Ruggeri L, CapanniM, Urbani E, Perruccio K, ShlomchikWD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
6. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530-5536.
7. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211-217.
8. SorrorML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446-452.
9. Baron F, Storer B, Maris MB, Storek J, Piette F, Metcalf M et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1176-1187.
10. Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine 2007; 86: 324-333.
11. Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O0Brien S et al. Transplant-lite: induction of graft-versusmalignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment of lymphoid malignancy. J Clin Oncol 1998; 16: 2817-2824.
12. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004; 32: 28-35.
13. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832-843.
14. Safdar A, Raad II.Management and treatment. In: O'Grady N, Pittet D (eds). Catheter-Related Infections in the Critically Ill. Kluwer Academic: Boston, 2004, pp, 99-112.
15. Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 2007; 45: 228-233.
16. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
17. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
18. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
19. Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukemia with X rays and homologous bone marrow; preliminary communication. Br Med J 1956; 32: 626-627.
20. Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981; 13: 248-251.
21. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
22. Slavin S, Eckerstein A, Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation-amplification of natural host defence mechanisms against cancer by recombinant IL-2. Nat Immun Cell Growth Regul 1988; 7: 180-184.
23. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
24. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graftversus- leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903-1909.
25. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
26. Porter D, Levine JE. Graft-versus-host disease and graftversus- leukemia after donor leukocyte infusion. Semin Hematol 2006; 43: 53-61.
27. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211-217.
28. Kumashi P, Girgawy E, Tarrand JJ, Rolston KV, Raad II, Safdar A. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002). Medicine 2005; 84: 303-312.
29. Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine 2007; 86: 69-77.
30. Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003; 31: 941-952. (Pubitemid 37211379)
31. Frère P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant 2006; 37: 411-418. (Pubitemid 43250476)
32. Zambelli A, Lilleri D, Pedrazzoli P, Peccatori J, Baldanti F, Fregoni V et al. Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11: 423-428.
33. Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004; 6: 171-178.
34. Daly A, McAfee S, Dey B, Colby C, Schulte L, Yeap B et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003; 9: 373-382.
35. EscalónMP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419-2423.
36. Busca A, Lovisone E, Aliberti S, Locatelli F, Serra A, Scaravaglio P et al. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 2003; 8: 303-311. (Pubitemid 37322187)
37. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690-697.
38. Busca A, Locatelli F, Barbui A, Ghisetti V, Cirillo D, Serra R et al. Ghisetti v. infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2003; 5: 132-139. (Pubitemid 37356356)
39. Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36: 9-15.
40. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744-2748.
41. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833. (Pubitemid 36917771)
42. Labbé AC, Su SH, Laverdière M, Pépin J, Patiño C, Cohen S et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007; 13: 1192-1200.
43. Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B et al. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol 2007; 82: 863-866.
44. Mielcarek M, Storer BE, Sandmaier BM, Sorror ML, Maloney DG, Petersdorf E et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant 2007; 13: 1499-1507. (Pubitemid 350091388)